New data on Journavx (suzetrigine) demonstrates effective pain management following aesthetic and reconstructive procedures – Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated announced data from a Phase IV study of Journavx (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults,… read more.
